- Press Releases
- Notices
Press Releases To List
-
- Mar.27.2023R & D
- ONO Receives Supplemental Approval of Opdivo in Combination with Chemotherapy for Neoadjuvant Treatment of Non-Small Cell Lung Cancer in Japan
-
- Mar.27.2023Sustainability
- ONO Sets New Targets of Medium- to Long-Term Environment Vision
- Toward Realization of Medium- to Long-Term Environment Vision, ECO VISION 2050 -
-
- Mar.23.2023R & D
- Opdivo® Intravenous Infusion Approved in South Korea for the First-line Treatment of Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in Two Combination Treatments of Opdivo + Yervoy and Opdivo + Chemotherapy
-
- Mar.23.2023Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
-
- Mar.23.2023Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with MOLCURE to Discover and Develop Innovative Antibody Drugs for Multiple Targets Utilizing MOLCURE’s AI-driven Platform Technology
Notices To List
-
- Sep.22.2022Corporate
- Announcement on posting of Corporate Report 2022
-
- Aug.31.2022Corporate
- Notifications regarding "Change of Domain" in our Website and Blocking to Receive Emails Containing "a Zip File with Password"
-
- Jun.24.2022Corporate
- Voting Results (Extraordinary Report) of the 74th Ordinary General Shareholders’ Meeting
-
- Jun.23.2022Corporate
- Notice to Resolutions Passed at The 74th Ordinary General shareholders’ Meeting
-
- May.26.2022Corporate
- Notice to Convene the 74th Ordinary General Shareholders’ Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
